BRAF-mutated CRC: testing to treatment

What's new for colorectal cancer treatment?Подробнее

BRAF-Mutated mCRC: From Diagnosis to TreatmentПодробнее

Role of Circulating Tumor Cells/DNA & Liquid Biopsy in Melanoma - David PolskyПодробнее

Initial Management of Metastatic CRC in 2019Подробнее

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRCПодробнее

Novel Agents and Targets in Colorectal CancerПодробнее

Optimizing Testing and Treatment of Patients with BRAFV600E-mutant mCRC in Community PracticeПодробнее

Highlights: BRAF-mutated CRC: testing to treatmentПодробнее

Dr. Andrea Cercek on CRC Treatment Options | WebinarПодробнее

Current status and perspectives on liquid biopsies in mCRCПодробнее

Debate: Are novel targets such as HER2 ready for prime time in colorectal cancer? - NoПодробнее

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRCПодробнее

Keynote Lecture 4: The BRAF pathway in CRC?Подробнее

Colorectal Cancer Debate: First Line BRAF V600E - FOLFOXIRI/BevПодробнее

Stratification in Cancer Medicine - Matthew GarnettПодробнее

Colorectal Cancer with acquired resistance to EGFR antibodies: How to manage?Подробнее

Case 1: Genomic Testing & NCCN Guidelines for Metastatic CRCПодробнее

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - EGFR antibodies are mandatoryПодробнее

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Bevacizumab or EGFR antibodiesПодробнее